|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Salani R and Bristow RE: Surgical
management of epithelial ovarian cancer. Clin Obstet Gynecol.
55:75–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaczmarek R: Alterations of Lewis
histo-blood group antigen expression in cancer cells. Postepy Hig
Med Dosw (Online). 64:87–99. 2010.(In Polish). PubMed/NCBI
|
|
5
|
Iwamori M, Iwamori Y, Kubushiro K,
Ishiwata I and Kiguchi K: Characteristic expression of
Lewis-antigenic glycolipids in human ovarian carcinoma-derived
cells with anticancer drug-resistance. J Biochem. 141:309–317.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao S, Liu Q, Wang X, Lin B and Zhang S:
Effects of Lewis y antigen on the gene expression of multiple drug
resistance-associated proteins in human ovarian cancer RMG-I-H
cells. Med Oncol. 27:960–967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ricardo S, Marcos-Silva L, Valente C,
Coelho R, Gomes R and David L: Mucins MUC16 and MUC1 are major
carriers of SLea and SLex in borderline and
malignant serous ovarian tumors. Virchows Arch. 468:715–722. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukushima K, Satoh T, Baba S and Yamashita
K: α1,2-Fucosylated and β-N-acetylgalactosaminylated
prostate-specific antigen as an efficient marker of prostatic
cancer. Glycobiology. 20:452–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Q, Liu S, Lin B, Yan L, Wang Y, Wang C
and Zhang S: Expression and correlation of Lewis y antigen and
integrins α5 and β1 in ovarian serous and mucinous carcinoma. Int J
Gynecol Cancer. 20:1482–1489. 2010.PubMed/NCBI
|
|
10
|
Madjd Z, Parsons T, Watson NF, Spendlove
I, Ellis I and Durrant LG: High expression of Lewisy/b
antigens is associated with decreased survival in lymph node
negative breast carcinomas. Breast Cancer Res. 7:R780–R787. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wakabayashi M, Shiro T, Seki T, Nakagawa
T, Itoh T, Imamura M, Shiozaki Y, Inoue K and Okamura A: Lewis y
antigen expression in hepatocellular carcinoma. An
immunohistochemical study. Cancer. 75:2827–2835. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Larsen RD, Ernst LK, Nair RP and Lowe JB:
Molecular cloning, sequence, and expression of a human
GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA
that can form the H blood group antigen. Proc Natl Acad Sci USA.
87:6674–6678. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watkins WM: Biochemistry and genetics of
the ABO, Lewis, and P blood group systems. Adv Hum Genet.
10(1–136): 379–185. 1980.
|
|
14
|
Oriol R: Genetic control of the
fucosylation of ABH precursor chains. Evidence for new epistatic
interactions in different cells and tissues. J Immunogenet.
17:235–245. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kelly RJ, Ernst LK, Larsen RD, Bryant JG,
Robinson JS and Lowe JB: Molecular basis for H blood group
deficiency in Bombay (Oh) and para-Bombay individuals. Proc Natl
Acad Sci USA. 91:5843–5847. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawai S, Kato S, Imai H, Okada Y and
Ishioka C: Suppression of FUT1 attenuates cell proliferation
in the HER2-overexpressing cancer cell line NCI-N87. Oncol Rep.
29:13–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hao YY, Lin B, Zhao Y, Zhang YH, Li FF,
Diao B, Ou YL and Zhang SL: Alpha1,2-fucosyltransferase gene
transfection influences on biological behavior of ovarian
carcinoma-derived RMG-I cells. FFen Zi Xi Bao Sheng Wu Xue Bao.
41:435–442. 2008.(In Chinese).
|
|
18
|
Liu Q, Lin B, Wang PL, Yan LM, Hao YY, Li
FF, Zhu LC and Zhang SL: Effect of Lewis y antigen on regulating
gene expression of partial drug resistance associated proteins in
human ovarian cancer cell line RMG-I-H. Zhongguo Yi Xue Ke Xue Yuan
Xue Bao. 31:481–487. 2009.(In Chinese). PubMed/NCBI
|
|
19
|
Shaulian E and Karin M: AP-1 in cell
proliferation and survival. Oncogene. 20:2390–2400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu ZG, Jiang G, Tang J, Wang H, Feng G,
Chen F, Tu Z, Liu G, Zhao Y, Peng MJ, et al: c-Fos over-expression
promotes radioresistance and predicts poor prognosis in malignant
glioma. Oncotarget. 7:65946–65956. 2016.PubMed/NCBI
|
|
21
|
Briso EM, Guinea-Viniegra J, Bakiri L,
Rogon Z, Petzelbauer P, Eils R, Wolf R, Rincón M, Angel P and
Wagner EF: Inflammation-mediated skin tumorigenesis induced by
epidermal c-Fos. Genes Dev. 27:1959–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y,
Zhuang H, Hu Z, Gao J, Yang Z, et al: c-Jun transcriptionally
regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer.
Biochimie. 107(Pt B): 286–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takemoto A, Okitaka M, Takagi S, Takami M,
Sato S, Nishio M, Okumura S and Fujita N: A critical role of
platelet TGF-β release in podoplanin-mediated tumour invasion and
metastasis. Sci Rep. 7:421862017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang C, Liu H, Gong XL, Wu LY and Wen B:
Effect of evodiamine and berberine on the interaction between DNMTs
and target microRNAs during malignant transformation of the colon
by TGF-β1. Oncol Rep. 37:1637–1645. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Witte D, Zeeh F, Gädeken T, Gieseler F,
Rauch BH, Settmacher U, Kaufmann R, Lehnert H and Ungefroren H:
Proteinase-activated receptor 2 is a novel regulator of TGF-β
signaling in pancreatic cancer. J Clin Med. 5:52016. View Article : Google Scholar :
|
|
28
|
Ru NY, Wu J, Chen ZN and Bian H:
HAb18G/CD147 is involved in TGF-β-induced epithelial-mesenchymal
transition and hepatocellular carcinoma invasion. Cell Biol Int.
39:44–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rafehi S, Ramos Valdes Y, Bertrand M,
McGee J, Préfontaine M, Sugimoto A, DiMattia GE and Shepherd TG:
TGFβ signaling regulates epithelial-mesenchymal plasticity in
ovarian cancer ascites-derived spheroids. Endocr Relat Cancer.
23:147–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheon DJ, Tong Y, Sim MS, Dering J, Berel
D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, et al: A
collagen-remodeling gene signature regulated by TGF-β signaling is
associated with metastasis and poor survival in serous ovarian
cancer. Clin Cancer Res. 20:711–723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alsina-Sanchis E, Figueras A, Lahiguera Á,
Vidal A, Casanovas O, Graupera M, Villanueva A and Viñals F: The
TGFβ pathway stimulates ovarian cancer cell proliferation by
increasing IGF1R levels. Int J Cancer. 139:1894–1903. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Massagué J: TGFβ signalling in context.
Nat Rev Mol Cell Biol. 13:616–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu L, Hébert MC and Zhang YE: TGF-beta
receptor-activated p38 MAP kinase mediates Smad-independent
TGF-beta responses. EMBO J. 21:3749–3759. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY,
Wang YF, Gao S, Qi Y, Zhang SL and Iwamori M: Expression and
correlation of Lewis y antigen and TGF-β1 in ovarian epithelial
carcinoma. Oncol Rep. 27:1065–1071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi M, Yu L, Hishikawa Y, Yamanoi A,
Kubota H and Nagasue N: Growth kinetic study of human
hepatocellular carcinoma using proliferating cell nuclear antigen
and Lewis y antigen: Their correlation with transforming growth
factor-alpha and beta 1. Oncology. 54:245–251. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai G, Hock TD, Logsdon N, Zhou Y and
Thannickal VJ: A far-upstream AP-1/Smad binding box regulates human
NOX4 promoter activation by transforming growth factor-β. Gene.
540:62–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Whitmarsh AJ and Davis RJ: Transcription
factor AP-1 regulation by mitogen-activated protein kinase signal
transduction pathways. J Mol Med. 74:589–607. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herr I and Debatin KM: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2614.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang Q, Lan F, Wang X, Yu Y, Ouyang X,
Zheng F, Han J, Lin Y, Xie Y, Xie F, et al: IL-1β-induced
activation of p38 promotes metastasis in gastric adenocarcinoma via
upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 13:182014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Muhammad N, Bhattacharya S, Steele R,
Phillips NJ and Ray RB: Involvement of c-Fos in the promotion of
cancer stem-like cell properties in head and neck squamous cell
carcinoma. Clin Cancer Res. 23:3120–3128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Motrich RD, Castro GM and Caputto BL: Old
players with a newly defined function: Fra-1 and c-Fos support
growth of human malignant breast tumors by activating membrane
biogenesis at the cytoplasm. PLoS One. 8:e532112013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong C, Ye DX, Zhang WB, Pan HY, Zhang ZY
and Zhang L: Overexpression of c-fos promotes cell invasion and
migration via CD44 pathway in oral squamous cell carcinoma. J Oral
Pathol Med. 44:353–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Halazonetis TD, Georgopoulos K, Greenberg
ME and Leder P: c-Jun dimerizes with itself and with c-Fos, forming
complexes of different DNA binding affinities. Cell. 55:917–924.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
DebRoy A, Vogel SM, Soni D, Sundivakkam
PC, Malik AB and Tiruppathi C: Cooperative signaling via
transcription factors NF-κB and AP1/c-Fos mediates endothelial cell
STIM1 expression and hyperpermeability in response to endotoxin. J
Biol Chem. 289:24188–24201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Basbous J, Jariel-Encontre I, Gomard T,
Bossis G and Piechaczyk M: Ubiquitin-independent-versus
ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1
transcription factors: Is there a unique answer? Biochimie.
90:296–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shaulian E and Karin M: AP-1 as a
regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Prusty BK and Das BC: Constitutive
activation of transcription factor AP-1 in cervical cancer and
suppression of human papillomavirus (HPV) transcription and AP-1
activity in HeLa cells by curcumin. Int J Cancer. 113:951–960.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Güller MC, André J, Legrand A, Setterblad
N, Mauviel A, Verrecchia F, Daniel F and Bernuau D: c-Fos
accelerates hepatocyte conversion to a fibroblastoid phenotype
through ERK-mediated upregulation of paxillin-Serine178
phosphorylation. Mol Carcinog. 48:532–544. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bassagañas S, Allende H, Cobler L, Ortiz
MR, Llop E, de Bolós C and Peracaula R: Inflammatory cytokines
regulate the expression of glycosyltransferases involved in the
biosynthesis of tumor-associated sialylated glycans in pancreatic
cancer cell lines. Cytokine. 75:197–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim SJ, Angel P, Lafyatis R, Hattori K,
Kim KY, Sporn MB, Karin M and Roberts AB: Autoinduction of
transforming growth factor beta 1 is mediated by the AP-1 complex.
Mol Cell Biol. 10:1492–1497. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Roy S, Khanna S, Azad A, Schnitt R, He G,
Weigert C, Ichijo H and Sen CK: Fra-2 mediates oxygen-sensitive
induction of transforming growth factor beta in cardiac
fibroblasts. Cardiovasc Res. 87:647–655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sullivan DE, Ferris M, Nguyen H, Abboud E
and Brody AR: TNF-alpha induces TGF-beta1 expression in lung
fibroblasts at the transcriptional level via AP-1 activation. J
Cell Mol Med. 13:1866–1876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim SJ, Glick A, Sporn MB and Roberts AB:
Characterization of the promoter region of the human transforming
growth factor-beta 1 gene. J Biol Chem. 264:402–408.
1989.PubMed/NCBI
|
|
55
|
Kunita A, Kashima TG, Ohazama A,
Grigoriadis AE and Fukayama M: Podoplanin is regulated by AP-1 and
promotes platelet aggregation and cell migration in osteosarcoma.
Am J Pathol. 179:1041–1049. 2011. View Article : Google Scholar : PubMed/NCBI
|
